Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HCM NASDAQ:IMVT NASDAQ:MOR NASDAQ:OCS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$17.93+9.5%$16.46$11.51▼$21.50$2.86B0.4551,431 shs92,782 shsIMVTImmunovant$16.16-3.8%$16.29$12.72▼$32.10$2.93B0.451.46 million shs2.86 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AOCSOculis$17.40+1.0%$17.67$11.78▼$23.08$751.87M0.2613,321 shs11,196 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED+9.53%+12.27%+12.06%+6.09%+6.66%IMVTImmunovant-3.81%-5.72%+1.70%+3.19%-44.37%MORMorphoSys0.00%0.00%0.00%0.00%0.00%OCSOculis+1.05%+1.05%-3.36%-8.52%+45.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$17.93+9.5%$16.46$11.51▼$21.50$2.86B0.4551,431 shs92,782 shsIMVTImmunovant$16.16-3.8%$16.29$12.72▼$32.10$2.93B0.451.46 million shs2.86 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AOCSOculis$17.40+1.0%$17.67$11.78▼$23.08$751.87M0.2613,321 shs11,196 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED+9.53%+12.27%+12.06%+6.09%+6.66%IMVTImmunovant-3.81%-5.72%+1.70%+3.19%-44.37%MORMorphoSys0.00%0.00%0.00%0.00%0.00%OCSOculis+1.05%+1.05%-3.36%-8.52%+45.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHCMHUTCHMED 2.33Hold$28.0056.16% UpsideIMVTImmunovant 2.83Moderate Buy$33.60107.92% UpsideMORMorphoSys 0.00N/AN/AN/AOCSOculis 3.00Buy$35.75105.46% UpsideCurrent Analyst Ratings BreakdownLatest OCS, IMVT, MOR, and HCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025HCMHUTCHMEDZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/4/2025IMVTImmunovantHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.008/27/2025OCSOculisNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.008/22/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $33.008/12/2025IMVTImmunovantJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $37.008/12/2025IMVTImmunovantBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$33.00 ➝ $30.008/11/2025IMVTImmunovantCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/11/2025HCMHUTCHMEDZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/28/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$17.00 ➝ $18.007/22/2025HCMHUTCHMEDBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $28.007/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold$18.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHCMHUTCHMED$630.20M4.96$0.31 per share56.99$4.43 per share4.05IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/AMORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17OCSOculis$780K973.95N/AN/A$1.91 per share9.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHCMHUTCHMED$37.73MN/A0.0012.28N/AN/AN/AN/AN/AIMVTImmunovant-$413.84M-$2.85N/AN/AN/AN/A-80.99%-72.23%11/6/2025 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/AOCSOculis-$97.43M-$2.67N/AN/AN/A-13,958.12%-90.31%-67.85%11/6/2025 (Estimated)Latest OCS, IMVT, MOR, and HCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025OCSOculis-$0.53-$0.59-$0.06-$0.59$0.14 million$0.25 million8/11/2025Q1 2026IMVTImmunovant-$0.69-$0.60+$0.09-$0.71N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHCMHUTCHMEDN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHCMHUTCHMED0.054.654.51IMVTImmunovantN/A12.3212.32MORMorphoSys4.981.381.38OCSOculis0.014.554.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHCMHUTCHMED8.82%IMVTImmunovant47.08%MORMorphoSys18.38%OCSOculis22.30%Insider OwnershipCompanyInsider OwnershipHCMHUTCHMED3.60%IMVTImmunovant1.80%MORMorphoSys0.05%OCSOculisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHCMHUTCHMED1,811174.42 million168.14 millionNot OptionableIMVTImmunovant120174.32 million171.18 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableOCSOculis243.66 millionN/ANot OptionableOCS, IMVT, MOR, and HCM HeadlinesRecent News About These CompaniesOCS-01 eye drop for DME performs equally well in phakic, pseudophakic eyesSeptember 9, 2025 | healio.comHOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesSeptember 9, 2025 | globenewswire.com131,332 Shares in Oculis Holding AG $OCS Acquired by Alyeska Investment Group L.P.September 8, 2025 | marketbeat.comOculis (NASDAQ:OCS) Sees Large Volume Increase - What's Next?September 5, 2025 | marketbeat.comOculis Holding AG (NASDAQ:OCS) Sees Large Increase in Short InterestSeptember 5, 2025 | marketbeat.comOculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025September 4, 2025 | globenewswire.comOculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025September 4, 2025 | globenewswire.comOculis Holding AG to Present Phase 2 ACUITY Trial Results for Privosegtor and Expanded Phase 3 DIAMOND Data at EURETINA CongressSeptember 1, 2025 | quiverquant.comQOculis Holding AG to Present Phase 2 and Phase 3 Clinical Trial Results at EURETINA and Other Key Ophthalmology ConferencesSeptember 1, 2025 | quiverquant.comQOculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology ConferencesSeptember 1, 2025 | globenewswire.comOculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology ConferencesSeptember 1, 2025 | globenewswire.comOculis (NASDAQ:OCS) Coverage Initiated at Needham & Company LLCAugust 29, 2025 | marketbeat.comOculis Holding AG Management to Participate in September Investor ConferencesAugust 28, 2025 | quiverquant.comQOculis Holding AG to Participate in Notable Investor Conferences in September 2025August 28, 2025 | quiverquant.comQOculis to Participate in Upcoming September Investor ConferencesAugust 28, 2025 | globenewswire.comOculis to Participate in Upcoming September Investor ConferencesAugust 28, 2025 | globenewswire.comOculis initiated with a Buy at NeedhamAugust 27, 2025 | msn.comOculis Holding AG $OCS Shares Bought by Pivotal bioVenture Partners Investment Advisor LLCAugust 26, 2025 | marketbeat.comOculis Holding AG Appoints Mark Kupersmith, M.D. and Sebastian Wolf, M.D., Ph.D. as Chief Medical Advisors in Neuro-Ophthalmology and Ophthalmology RespectivelyAugust 25, 2025 | quiverquant.comQOculis Holding AG Appoints Mark Kupersmith, M.D. and Sebastian Wolf, M.D., Ph.D. as Chief Medical Advisors to Lead Advances in Neuro-Ophthalmology and OphthalmologyAugust 25, 2025 | quiverquant.comQOculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.August 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMongoDB Roars Back to Life: It’s Not Too Late to Buy MoreBy Thomas Hughes | August 27, 2025Alphabet’s Breakout Potential: From Laggard to AI LeaderBy Ryan Hasson | August 22, 2025TJX Stock Price Hits Fresh High, Signals More Highs to FollowBy Thomas Hughes | August 22, 2025Eyes on the Sky: AST SpaceMobile Prepares for Commercial LaunchBy Jordan Chussler | September 8, 20253 Undervalued Stocks Analysts Are Loving Right Now—Should You?By Gabriel Osorio-Mazilli | August 27, 2025OCS, IMVT, MOR, and HCM Company DescriptionsHUTCHMED NASDAQ:HCM$17.93 +1.56 (+9.53%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$17.92 -0.02 (-0.08%) As of 09/12/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Immunovant NASDAQ:IMVT$16.16 -0.64 (-3.81%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$16.28 +0.13 (+0.77%) As of 09/12/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 09/12/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Oculis NASDAQ:OCS$17.40 +0.18 (+1.05%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$17.43 +0.04 (+0.20%) As of 09/12/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
